Biodesix's New Analysis From ORACLE Study Showed Patients With Benign Lung Nodules Managed With The Test Were 74% Less Likely To Undergo Unnecessary Invasive Procedure Compared To Control Group, Representing 51% Relative Increase In Cancer Diagnosis Rate
Portfolio Pulse from Benzinga Newsdesk
Biodesix's new analysis from the ORACLE study showed that patients with benign lung nodules managed with the Nodify XL2 test were 74% less likely to undergo unnecessary invasive procedures compared to the control group. This represents a 51% relative increase in cancer diagnosis rate. The proportion of patients sent to CT surveillance with malignant nodules did not differ between the Nodify XL2 group and the control group.
August 22, 2023 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodesix's Nodify XL2 test has shown significant potential in reducing unnecessary invasive procedures and increasing cancer diagnosis rate. This could potentially increase the demand for the test, positively impacting Biodesix's revenues.
The positive results from the ORACLE study could increase the demand for Biodesix's Nodify XL2 test. This could lead to an increase in the company's revenues, which would likely have a positive impact on the stock price. The news is highly relevant as it directly pertains to one of the company's products and its potential market impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100